SCHEDULE: Jorey Chernett Discloses 19.6% Stake in Kazia Therapeutics

Jorey Chernett has filed a Schedule 13G, reporting beneficial ownership of 2,339,009 American Depositary Shares, representing 19.6% of the outstanding class in Kazia Therapeutics Ltd.

Summary

• Jorey Chernett has filed a Schedule 13G, indicating a significant ownership stake in Kazia Therapeutics Ltd.
• The filing reports beneficial ownership of 2,339,009 American Depositary Shares (ADS).
• This ownership represents 19.6% of the total outstanding ADSs.
• The reporting person has sole voting and dispositive power over these shares.
• The filing is an amendment (Amendment No. 4) to a previous filing.
• The event triggering this filing is dated August 5, 2026, with the reporting date of August 19, 2026.
• The total number of outstanding ADSs is stated as 11,926,899 as of August 19, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily an ownership disclosure without significant new financial or strategic information.

Positives

• Significant ownership stake by Jorey Chernett, potentially indicating strong investor conviction.
• Clear disclosure of beneficial ownership, providing transparency to the market.

Negatives

• No new financial performance data or strategic updates are provided in this filing.
• The filing is an amendment, suggesting prior disclosures were made, but the specific changes are not detailed here.

Risks

• The filing does not detail the purpose of the ownership, which could be for investment or control, introducing uncertainty.
• Concentration of ownership could lead to potential influence on company decisions, which may or may not align with other shareholders' interests.

Future Outlook

This filing does not contain any forward-looking statements or guidance.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."
• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

StockSavvy.ai notes that significant ownership disclosures like this Schedule 13G are common in the biotechnology and pharmaceutical sectors, where substantial investment is often required, and key stakeholders may accumulate large positions.

Stakeholder Impact

• Shareholders: Increased transparency regarding a major shareholder's stake, potentially influencing market perception and trading activity.
• Management: May face increased scrutiny or influence from a significant shareholder with a 19.6% stake.

Key Dates

Keywords

Kazia Therapeutics, Schedule 13G, Ownership, American Depositary Shares, Beneficial Ownership, Jorey Chernett, SEC Filing